Promising phase II results in chronic kidney disease
Boehringer Ingelheim’s investigation of novel compound on top of standard of care empagliflozin shows promising results for chronic kidney disease
Search
Boehringer Ingelheim annouces 2020 BVDzero Case Awards
Boehringer Ingelheim is announcing the 2020 ‘BVDzero Case Awards’ are now open for applications. The bi-annual awards reflect the long-term commitment to promoting the health and well-being of farm animals.
New study paves the way for liver cirrhosis treatments
The ADVANCE study will be the most detailed observational study of its kind providing a detailed analysis of liver health.
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Connect with Us
Human Health Partnering Connect with Us
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
History
History
Fornovo
With its production facilities, Fornovo San Giovanni constitutes an important site for the production of core active pharmaceutical ingredients for both Human Pharma and Animal Health.
Generalized pustular psoriasis: The Impact Beyond The Skin
An article on how the symptoms of generalized pustular psoriasis (GPP) are more than just physical, affecting both mental and emotional health
Scouting for digital innovation
Get to know our digital scouts who look-out for emerging technologies and trends that could benefit our patients.
World Patient Safety Day 2021
As a sign of support for World Patient Safety Day, Boehringer Ingelheim lights up buildings in orange.
COVID-19
As a research-driven company, we are part of the collective effort in fighting COVID-19. Learn more about our ongoing engagement in the fight against COVID-19
Swine
Swine
Cat vaccination 10 things you should know
Find out how you can keep your feline companion happy and healthy.
Thank you for submitting your report
multistep form
Schizophrenia
Schizophrenia
Heart Diseases
Heart Diseases
Patient Safety & Pharmacovigilance at Boehringer Ingelheim
Patients inspire us in our mission to lead the science that creates breakthrough therapies, so that our medicines transform patients’ lives.
Annual Results Press Conference
Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Contact Us
Contact our partnering team to discuss your project and learn more about how we can work together.
Expert insights: the top online lung cancer questions answered
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Overcoming stigma and advancing lung cancer advocacy
Lung cancer advocates highlight the need to overcome stigma, access reliable info, and implement early diagnosis and screening.
Corporate Profile
Corporate Profile
Elke
People with Type 2 diabetes (T2D) have an increased risk of heart disease.
Company Culture
Company Culture